D. Allen Annis

3.1k citations

26 papers · 1.4k indexed · h-index 19

Co-authors: Eric N. Jacobsen Michael R. Ziebell Charles E. Whitehurst Elliot Nickbarg Huw M. Nash Xianshu Yang Manuel Aivado Vincent Guerlavais
Topics: Chemical Synthesis and Analysis (9 papers)Ubiquitin and proteasome pathways (7 papers)Cancer-related Molecular Pathways (5 papers)
Cited by: Organic Chemistry Inorganic Chemistry Molecular Biology
Journals: Journal of the American Chemical Society Angewandte Chemie International Edition Journal of Clinical Oncology
Partner nations: United States Sweden France

In The Last Decade

D. Allen Annis

26 papers receiving 1.4k citations

Peers

Countries citing papers authored by D. Allen Annis

Since Specialization

Citations

This map shows the geographic impact of D. Allen Annis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Allen Annis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Allen Annis more than expected).

Fields of papers citing papers by D. Allen Annis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Allen Annis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Allen Annis. The network helps show where D. Allen Annis may publish in the future.

Co-authorship network of co-authors of D. Allen Annis

This figure shows the co-authorship network connecting the top 25 collaborators of D. Allen Annis. A scholar is included among the top collaborators of D. Allen Annis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Allen Annis. D. Allen Annis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity 2021 ·Cancer Discovery ·Xiaolei Zhou,Madhurendra Singh,Gema Sanz,Vincent Guerlavais,Luis A. Carvajal,Manuel Aivado,Yue Zhan,Mariana M.S. Oliveira,Lisa S. Westerberg,D. Allen Annis,John Inge Johnsen,Galina Selivanova	113
2	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 2021 ·Clinical Cancer Research ·Mansoor N. Saleh,Manish R. Patel,Todd M. Bauer,Sanjay Goel,Gerald S. Falchook,Geoffrey I. Shapiro,Ki Y. Chung,Jeffrey R. Infante,Robert M. Conry,Guilherme Rabinowits,David S. Hong,Judy S. Wang,Ulrich Steidl,Gurudatta Naik,Vincent Guerlavais,Vojislav Vukovic,D. Allen Annis,Manuel Aivado,Funda Meric‐Bernstam	110
3	MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma 2021 ·Scientific Reports ·Sarah E. Woodfield,Yan Shi,Roma H. Patel,Zhenghu Chen,(unknown),Rohit Srivastava,Richard S. Whitlock,(unknown),(unknown),Stephen F. Sarabia,Andrew Badachhape,Zbigniew Starosolski,Ketan B. Ghaghada,Pavel Sumazin,D. Allen Annis,Dolores López‐Terrada,Sanjeev A. Vasudevan	24
4	Solving the Competitive Binding Equilibria between Many Ligands: Application to High-Throughput Screening and Affinity Optimization 2020 ·Analytical Chemistry ·Vincent Blay,Irene Otero‐Muras,D. Allen Annis	5
5	Exploring new targets and chemical space with affinity selection-mass spectrometry 2020 ·Nature Reviews Chemistry ·Renaud Prudent,D. Allen Annis,Peter J. Dandliker,Jean‐Yves Ortholand,Didier Roche	58
6	Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type 2018 ·Blood ·David A. Sallman,Uma Borate,Elizabeth H. Cull,William B. Donnellan,Rami S. Komrokji,Ulrich Steidl,(unknown),(unknown),D. Allen Annis,(unknown),Manuel Aivado,Amit Verma	27
7	Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2 2018 ·Blood ·Andrei R. Shustov,Amitkumar Mehta,Lubomir Sokol,Luis A. Carvajal,Vincent Guerlavais,Manoj Samant,Narayana I. Narasimhan,David Sutton,D. Allen Annis,(unknown),Manuel Aivado,Ronald L. Korn	4
8	Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma 2018 ·Blood ·Andrei R. Shustov,Steven M. Horwitz,Jasmine Zain,Manish R. Patel,Sanjay Goel,Lubomir Sokol,Funda Meric‐Bernstam,Geoffrey I. Shapiro,Sunita D. Nasta,Murali Janakiram,David M. Weinstock,Ronald L. Korn,(unknown),D. Allen Annis,(unknown),Manuel Aivado,Amitkumar Mehta	7
9	Phase 2a study of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of wild-type TP53 in patients with peripheral t-cell lymphoma 2017 ·Annals of Oncology ·(unknown),(unknown),Amitkumar Mehta,Sanjay Goel,Jasmine Zain,Lubomir Sokol,Eric D. Jacobsen,Manish R. Patel,Steven M. Horwitz,Funda Meric‐Bernstam,Andrei R. Shustov,David M. Weinstock,Manuel Aivado,D. Allen Annis	8
10	Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. 2017 ·Journal of Clinical Oncology ·Funda Meric‐Bernstam,Mansoor N. Saleh,Jeffrey R. Infante,Sanjay Goel,Gerald S. Falchook,Geoffrey I. Shapiro,Ki Y. Chung,Robert M. Conry,David S. Hong,(unknown),Ulrich Steidl,Loren D. Walensky,Vincent Guerlavais,(unknown),D. Allen Annis,Manuel Aivado,Manish R. Patel	62
11	Hydrogen Exchange-Mass Spectrometry Measures Stapled Peptide Conformational Dynamics and Predicts Pharmacokinetic Properties 2013 ·Analytical Chemistry ·Xiangguo Shi,Thomas E. Wales,Carl Elkin,(unknown),John R. Engen,D. Allen Annis	18
12	Novel Benzimidazole Inhibitors Bind to a Unique Site in the Kinesin Spindle Protein Motor Domain 2010 ·Biochemistry ·Payal R. Sheth,Gerald W. Shipps,Wolfgang Seghezzi,Catherine K. Smith,Cheng‐Chi Chuang,(unknown),Andrea Basso,L.Z. Vilenchik,Kimberly Gray,D. Allen Annis,Elliott Nickbarg,Yao Ma,Brian R. Lahue,Ronald Herbst,Hung V. Le	25
13	Calcium indirectly regulates immunochemical reactivity and functional activities of the N-domain of thrombospondin-1 2008 ·Matrix Biology ·Marı́a J. Calzada,Светлана А. Кузнецова,John M. Sipes,(unknown),(unknown),D. Allen Annis,D F Mosher,David D. Roberts	18
14	Affinity selection-mass spectrometry screening techniques for small molecule drug discovery 2007 ·Current Opinion in Chemical Biology ·D. Allen Annis,Elliot Nickbarg,Xianshu Yang,Michael R. Ziebell,Charles E. Whitehurst	158
15	Method for Quantitative Protein−Ligand Affinity Measurements in Compound Mixtures 2007 ·Analytical Chemistry ·D. Allen Annis,Gerald W. Shipps,Yongqi Deng,Janeta Popovici-Müller,M. Arshad Siddiqui,(unknown),(unknown),William T. Windsor	37
16	Discovery and Characterization of Orthosteric and Allosteric Muscarinic M2 Acetylcholine Receptor Ligands by Affinity Selection–Mass Spectrometry 2006 ·SLAS DISCOVERY ·Charles E. Whitehurst,Naim Nazef,D. Allen Annis,(unknown),Denise Murphy,Peter Spacciapoli,Zhiping Yao,Michael R. Ziebell,Cliff C. Cheng,Gerald W. Shipps,(unknown),David H. Lau,Huw M. Nash	24
17	An affinity selection–mass spectrometry method for the identification of small molecule ligands from self-encoded combinatorial libraries 2004 ·International Journal of Mass Spectrometry ·D. Allen Annis,(unknown),(unknown),(unknown),Krishna Kalghatgi,(unknown),Huw M. Nash,(unknown),K Rösner,Gerald W. Shipps,(unknown),Andrew N. Tyler,L.Z. Vilenchik,Carston R. Wagner,Edward A. Wintner	74
18	ChemInform Abstract: Polymer‐Supported Chiral Co(Salen) Complexes: Synthetic Applications and Mechanistic Investigations in the Hydrolytic Kinetic Resolution of Terminal Epoxides. 1999 ·ChemInform ·D. Allen Annis,Eric N. Jacobsen	11
19	Polymer-Supported Chiral Co(Salen) Complexes: Synthetic Applications and Mechanistic Investigations in the Hydrolytic Kinetic Resolution of Terminal Epoxides 1999 ·Journal of the American Chemical Society ·D. Allen Annis,Eric N. Jacobsen	359
20	Stereochemische Eigenschaften als Diversitätselement: Festphasensynthese cyclischer RGD-Peptidderivate via asymmetrische Katalyse 1998 ·Angewandte Chemie ·D. Allen Annis,(unknown),Eric N. Jacobsen	16

About D. Allen Annis

D. Allen Annis is a scholar working on Molecular Biology, Spectroscopy and Oncology, having authored 26 papers that have together received 1.4k indexed citations. Recurring topics across this work include Chemical Synthesis and Analysis (9 papers), Ubiquitin and proteasome pathways (7 papers) and Cancer-related Molecular Pathways (5 papers). The work is most often cited by research in Organic Chemistry (430 citations), Inorganic Chemistry (180 citations) and Molecular Biology (863 citations). D. Allen Annis has collaborated with scholars based in United States, Sweden and France. Frequent co-authors include Eric N. Jacobsen, Michael R. Ziebell, Charles E. Whitehurst, Elliot Nickbarg, Huw M. Nash, Xianshu Yang, Manuel Aivado, Vincent Guerlavais, Cheng‐Chi Chuang and Naim Nazef. Their work appears in journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact